"They Know Cardia...."
US-based Safety Pharmacology Head, Top 10 Global Pharma


Summary
Did you know that cardiotoxicity is the second largest cause of Pharma R&D failure?
To help you succeed where others fail - we have built a set of uniquely predictive cardiotoxicity assays; We provide
  • The fastest and lowest cost method of assessing cardiotoxicity  - The Cardiotoxome in silico
  • The Unique, Award-Winning cardiac contractility & Excitation Coupling model - The Work Loop in vitro
  • Industry standard models that support your regulatory filings - ex vivo
  • Experts that can help you interpret your external datasets
We can provide cardiotoxicity insight from before you make your first compound through to filling your IND.
For prices, quotes, or to find out more - click here.
Our Products

About InoCardia

We are a UK-based, specialist provider of  cardiotoxicity assessment services for Pharma & Biotech customers - In fact, we cover more of pharma research than any other provider*.

InoCardia brings superior, predictive, Award-Winning cardio-toxicity assays to pharmaceutical R&D.   

 Our technologies have received multiple grant awards. We recently completed (i) a 3-year, NC3R/InnovateUK project to miniaturise our Work Loop platform, (ii) An EIT Digital supported consortium to develop the first in silico/AI product able to identify cardiac contractility - 'The Contractome' and (iii) a project to assess cardiotoxicity in potential COVID-19 antivirals.  

*InoCardia is the only provider offering predictive cardiotoxicity assessment through Design, Hit, Lead, Candidate Nomination and Regulatory stages of Pharma R&D.

Work Loop

Work Loop models are considered the gold standard of in vitro inotropy measurement. We manipulate pre- and after-load whilst simultaneously measuring the microscopic forces generated in heart muscles and myocytes. The Work Loop model can be considered as an in vitro version of the pressure volume loop.  

Work Loop is diagnostic of both contractility and excitation coupling abnormalities and can provide insight into a drug's mode of action. 

Work Loop has been characterised against over 70 cardiotoxic mechanisms and drugs.

For rapid ordering & delivery vist InoCardia at the Scientist.com online marketplace

CardioToxome

CardioToxome offers the earliest possible opportunity to identify cardiotoxicity currently available given no physical sample is required.

Built entirely from human clinical data, CardioToxome is an innovative new Safety Pharmacology concept that dramatically reduces the cost & time required to assess new drugs and is as predictive as in vitro ion-channel & cardiac safety panels combined. 

 CardioToxome studies can be ordered directly from Scientist.com or by contacting us below. 

CardioToxome builds on our 'Contractome-AI' breakthrough product developed in collaboration with Cresset BioMolecules, UCB Pharma and Coventry University, and supported by EIT Digital (Horizon 2020), taking it to a new level.  Fact Sheet@EITDigital   

For Rapid Ordering & Delivery visit InoCardia at the Scientist.com online marketplace

Regulatory & Bespoke Studies

Our scientific team have wide expertise and knowledge in the safety pharmacology field. We offer the Langendorff model, a well studied and characterised model  accepted by regulators and researchers alike. 

We offer a more cost-effective alternative than your current provider, please contact us for a quote.

Need to find out more about your experimental drugs? Want to link your in vitro results to possible inotropy mechanism? Want to screen compound library exemplars for cardiotox when you dont have enough sample? Need a bespoke assay developing? 

 Then get in touch with us.

For Rapid Ordering & Delivery visit InoCardia at the Scientist.com online marketplace

Our Team
InoCardia has a highly experienced safety pharmacology team and world-leading cardiotoxicty. expertise. The team has unique expertise in the complex manipulation of tissue and myocyte required to support cardiotoxicity studies.
Professor Helen Maddock
Helen is founder and CSO of InoCardia, and Professor of Cardiovascular Physiology & Pharmacology.  She has over 27 years’ experience of pharmaceutical related R&D and author of many drug safety and cardiovascular pharmacology related publications.
Dr Jeremy Billson
Jeremy has been InoCardia's CEO since 2016. Prior to this he held senior commercial and drug discovery research roles in the Biotech and research services sectors.
InoCardia's labs and offices are sited in Coventry, UK. In 2019 we moved into our new, purpose built CardioTox lab within the Alison Gingell SuperLab at Coventry University, in early 2020 we doubled our in vitro myocyte screening capacity and in 2021 we extended our Langendorff screening capacity.
News

18 - 03 - 2023

InoCardia wins 2023 MediLink Midlands 'One-To-Watch' Award

28 - 01 - 2022

InoCardia technologies recognised with Women In Innovation Award

24 - 09 - 2021

We Are Presenting Our Contractome Technologies At SPS2021, Come Join Us

07 - 12 - 2020

SPS Technology Innovation Award for Coventry University & InoCardia

18 - 06 - 2020

InoCardia receives funding to help fight COVID-19 from UK government 

09 - 06 - 2020

Press Release: In Silico Assay Development Collaboration

12 - 04 - 2018

19 - 03 - 2018

InoCardia on YouTube

Contact Us
Please contact us using this form or via the email or phone number below

Email: info@inocardia.com
Phone: +44 (0)7988 563489

InoCardia Ltd, The TechnoCentre, Puma Way, Coventry, CV1 2TT, UK